New Paclitaxel Therapy Findings from National Cancer Institute Outlined (Polylactide-Based Paclitaxel-Loaded Nanoparticles Fabricated by Dispersion Polymerization: Characterization, Evaluation in Cancer Cell Lines, and Preliminary ...)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting originating in Bethesda, Maryland, by NewsRx journalists, research stated, "The macromonomer method was used to prepare cross-linked, paclitaxel-loaded polylactide (PLA)-polyethylene glycol (stealth) nanoparticles using free-radical dispersion polymerization. The method can facilitate the attachment of other molecules to the nanoparticle surface to make it multifunctional."
The news reporters obtained a quote from the research from National Cancer Institute, "Proton nuclear magnetic resonance and Fourier transform infrared spectra confirm the synthesis of PLA macromonomer and cross-linking agent. The formation of stealth nanoparticles was confirmed by scanning and transmission electron microscopy. The drug release isotherm of paclitaxel-loaded nanoparticles shows that the encapsulated drug is released over 7 days. In vitro cytotoxicity assay in selected breast and ovarian cancer cell lines reveal that the blank nanoparticle is biocompatible compared with medium-only treated controls. In addition, the paclitaxel-loaded nanoparticles exhibit similar cytotoxicity compared with paclitaxel in solution. Confocal microscopy reveals that the nanoparticles are internalized by MCF-7 breast cancer cells within 1 h. Preliminary biodistribution studies also show nanoparticle accumulation in tumor xenograft model."
According to the news reporters, the research concluded: "The nanoparticles are suitable for the controlled delivery of bioactive agents."
For more information on this research see: Polylactide-Based Paclitaxel-Loaded Nanoparticles Fabricated by Dispersion Polymerization: Characterization, Evaluation in Cancer Cell Lines, and Preliminary Biodistribution Studies. Journal of Pharmaceutical Sciences, 2014;103(8):2546-2555. Journal of Pharmaceutical Sciences can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Pharmaceutical Sciences - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017)
Our news correspondents report that additional information may be obtained by contacting S.K. Adesina, National Cancer Institute, Radiat Oncol Branch, National Institutes of Health, Bethesda, MD 20892, United States. Additional authors for this research include A. Holly, G. Kramer-Marek, J. Capala and E.O. Akala (see also Drugs and Therapies).
Keywords for this news article include: Bethesda, Maryland, United States, North and Central America, Antineoplastics, Cancer, Cycloparaffins, Drugs, Drugs and Therapies, Emerging Technologies, Hydrocarbons, Mitotic Inhibitors, Nanoparticle, Nanotechnology, Oncology, Organic Chemicals, Paclitaxel, Pharmaceuticals, Taxoids, Terpenes, Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC